Extracts of Feverfew (Tanacetum Parthenium)
Total Page:16
File Type:pdf, Size:1020Kb
Europäisches Patentamt *EP001100516B1* (19) European Patent Office Office européen des brevets (11) EP 1 100 516 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 35/78, A61P 29/00 of the grant of the patent: 23.03.2005 Bulletin 2005/12 (86) International application number: PCT/US2000/015125 (21) Application number: 00938038.7 (87) International publication number: (22) Date of filing: 02.06.2000 WO 2000/074699 (14.12.2000 Gazette 2000/50) (54) EXTRACTS OF FEVERFEW (TANACETUM PARTHENIUM) AGAINST INFLAMMATORY DISORDERS EXTRAKTE VON MUTTERKRAUT (TANACETUM PARTHENIUM) GEGEN ENTZÜNDLICHE ERKRANKUNGEN EXTRAITS DE CHRYSANTEME-MATRICAIRE (TANACETUM PARTHENIUM) UTILISES CONTRE LES TROUBLES INFLAMMATOIRES (84) Designated Contracting States: • ODDOS, Thierry AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU F-92190 Meudon (FR) MC NL PT SE • GENDIMENICO, Gerard, J., Neshanic Station, NJ 08853 (US) (30) Priority: 03.06.1999 US 137332 P • MARTIN, Katharine Ringoes, NJ 08551 (US) (43) Date of publication of application: 23.05.2001 Bulletin 2001/21 (74) Representative: Ahner, Francis et al Cabinet Régimbeau (73) Proprietors: 20, rue de Chazelles • Johnson & Johnson Consumer France SAS 75847 Paris cedex 17 (FR) 92787 Issy les Moulineaux Cedex 9 (FR) • Callaghan, Theresa (56) References cited: 2613 AX Delft (NL) • DATABASE BIOSIS [Online] BIOSCIENCES • Oddos, Thierry INFORMATION SERVICE, PHILADELPHIA, PA, 92190 Meudon (FR) US; 1993 BARASBY RWJETAL:"Feverfew and • Gendimenico, Gerard J. vascular smooth muscle: Extracts from fresh Neshanic Station, NJ 08853 (US) and dried plants show opposing • Martin, Katharine pharmacological profiles, dependent upon Ringoes, NJ 08551 (US) sesquiterpene lactone content." Database accession no. PREV199395123206 XP002147441 (72) Inventors: & PLANTA MEDICA, vol. 59, no. 1, 1993, pages • CALLAGHAN, Theresa 20-25, ISSN: 0032-0943 NL-2613 AX Delft (NL) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 100 516 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 100 516 B1 Description FIELD OF THE INVENTION 5 [0001] This invention relates to the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium). BACKGROUND OF THE INVENTION 10 [0002] Tanacetum parthenium, a plant commonly known as Feverfew, has been recognized since the Middle Ages as having significant medicinal properties when taken orally - used as a general febrifuge, hence its common name. Many have isolated extracts of the plant and those extracts have been used to orally treat migraines, arthritis, and bronchial complaints. (See Johnson et al, US Patent 4,758,433, discussing the treatment of a variety of diseases by oral, inhalation, injection or suppository administration of the extract and see WO 94 06800, discussing a extract of 15 feverfew which contains parthenolide). [0003] Extracts of feverfew contain many components. Although not all components have been isolated and char- acterized, the known components of an extract of feverfew contain a significant number of biologically active compo- nents. To date, the chemical constituents of whole feverfew extract are as follows: apigenin-7-glucoside, apigenin- 7-glucuronide, 1-β-hydroxyarbusculin, 6-hydroxykaempferol-3,7-4'-trimethylether (Tanetin), 6-hydroxykaempferol- 20 3,7-dimethyl ether, 8-β-reynosin, 10-epicanin, ascorbic acid, beta-carotene, calcium, chromium, chrysanthemolide, chrysanthemomin, chrysarten-A, chrsyarten-c, chrysoeriol-7-glucuronide, cobalt, cosmosiin, epoxyartemorin, luteolin- 7-glucoside, luteolin-7-glucuronide, mangnoliolide, parthenolide, quercetagentin-3,7,3'-trimethylether, quercetagetin- 3'7-dimethylether, reynosin, tanaparthin, tanaparthin-1α,4α-epoxide, tanaparthin-1β,4β-epoxide, β-costunolide, 3-β- hydroxy-parthenolide, and 3,7,3'-trimethoxyquercetagetin. The specific role that each of these component compounds 25 plays in the biological activity of feverfew is to date unknown. However, some information is known about the allergic reactions to the extract. It is believed that many of these allergic reactions are caused by the α-unsaturated γ-lactones such as parthenolide. (See, Arch. Dermatol. Forsch. 1975, 251 (3):235-44; Arch. Dermatol Forsch 1976, 255 (2):111-21; Contact Dermatitis, 1988, 38 (4):207-8; Am. J. Contact Dermatol. 1998-9 (1):49-50; Br. J. Dermatol, 1995, 132 (4): 543-47). 30 [0004] Despite the existence of oral methods of using extracts of feverfew, there are no defined methods for topically using these extracts to treat or prevent inflammatory disorders and related conditions. In addition, there are no teachings which describe the use of an extract of feverfew which does not contain the allergy causing α-unsaturated γ-lactones. These are two areas which are addressed by this invention. 35 SUMMARY OF THE INVENTION [0005] This invention relates to the use of an extract of feverfew for the preparation of a topical composition for treating or preventing inflammatory disorders and related conditions. The use of this invention includes the use where inflammatory disorders and related conditions are related to the skin. Still further, the invention includes the use of an 40 extract of feverfew where said extract is substantially free of α-unsaturated γ-lactone. Further, the invention includes the use of an extract of feverfew for treating and preventing inflammatory disorders and related conditions of the skin where said extract is substantially free of α-unsaturated lactone. DETAILED DESCRIPTION OF THE INVENTION 45 [0006] This invention includes the use of an extract of feverfew for the preparation of a topical composition for treating and preventing inflammatory disorders and related conditions. [0007] Inflammatory disorders and related conditions which may be treated or prevented by topical use of the com- positions of this invention include, but are not limited to the following: arthritis, bronchitis, contact dermatitis, atopic 50 dermatitis, psoriasis, seborrheic dermatitis, eczema, allergic dermatitis, polymorphous light eruptions, inflammatory dermatoses, folliculitis5 alopecia, poison ivy, insect bites, acne inflammation, irritation induced by extrinsic factors in- cluding, but not limited to, chemicals, trauma, pollutants (such as cigarette smoke) and sun exposure, secondary con- ditions resulting from inflammation including but not limited to xerosis, hyperkeratosis, pruritus, post-inflammatory hy- perpigmentation, scarring and the like. Preferably, the inflammatory disorders and related conditions which may be 55 treated or prevented using the methods of the invention are arthritis, inflammatory dermatoses, contact dermatitis, allergic dermatitis, atopic dermatitis, polymorphous light eruptions, irritation, including erythema induced by extrinsic factors, acne inflammation, psoriasis, seborrheic dermatitis, eczema, poison ivy, insect bites, folliculitus, alopecia, and secondary conditions and the like. 2 EP 1 100 516 B1 [0008] "Feverfew** is a plant belonging to the family of Asteraceae/Composite which is technically known as, Tan- acetum parthenium, Altamisa, Crisanthemum, Leucanthemum, or Pyrethrum parthenium. [0009] The term "effective amount" refers to the percentage by weight of the feverfew extract in the topical compo- sition which is needed to treat an inflammatory disorder or related condition in a patient. Preferably the effective amount 5 is between about 0.0005 to about 20% by weight of the composition. More preferably, the concentration should be less than about 10% by weight of the topical composition. Even more preferably between about 0.001% and about 10%, and most preferably between about 0.01% and about 2%« [0010] The term "patient" refers to a mammal which is being treated prophylactically for an inflammatory condition and/or for an inflammatory condition with visible symptoms. Preferably the patient is a human. 30 Further, the invention 10 includes the use of a composition containing an extract of feverfew for treating and preventing inflammatory disorders and related conditions of the skin. [0011] The terms, inflammatory disorder and related condition, feverfew, effective amount, and patient, have their aforementioned meanings. The term skin" includes all surfaces of a patient, such as the exposed hide or surfaces covered by hair. 15 [0012] The invention also includes the use of an extract of feverfew where said extract is α-unsaturated γ-lactone- deprived. [0013] The terms, inflammatory disorders and related conditions, feverfew, effective amount, and patient have their aforementioned meanings. The term "substantially free of α-unsaturated γ-lactone", refers to an extract of feverfew having a weight content of the α-unsaturated γ-lactones found in natural feverfew extracts of less than about 0.2% by 20 weight. These α-unsaturated γ-lactones include but are not limited to parthenolide ([1αR-(1a R*, 4E, 7a S*, 10a S*, 10b R*)]2,3,4,7,7a,8,10a, 10b-octahydro-la,5-dimethyl-8-4,5α-epoxy-6β-hydroxy- germacra-1(10),11(13)-dien-12-oic acid γ-lactone), 3-β-hydroxy-parthenolide, costunolide, 3-β-constunolide,artemorin, 8-α-hydroxy-estafiatin, chysan- themolide, magnoliolide, tanaparthin, tanaparthin-1α,4α-epoxide,